Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease

Antonio Nenna ¹; Francesco Nappi ²; Sanjeet Singh Avtaar Singh ³; Fraser W. Sutherland ³; Fabio Di Domenico ⁴; Massimo Chello ¹; Cristiano Spadaccio ³,*

¹Department of Cardiovascular Sciences, Rome University of Campus Bio Medico, Rome, Italy
²Cardiac Surgery Centre Cardiologique du Nord de Saint-Denis, Paris, France
³Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Clydebank, Glasgow, UK
⁴Department of Biochemical Sciences, La Sapienza University of Rome, Rome, Italy
*Corresponding author: Cristiano Spadaccio, Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Clydebank, Glasgow, UK. Tel: +44-1419515000, Fax: +44-1419515006, E-mail: Cristiano.spadaccio@gjnh.scot.nhs.uk

Received: January 13, 2015; Revised: February 6, 2015; Accepted: February 17, 2015

Context: Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and neurological complications in diabetic and non-diabetic patients. AGEs proved to be a marker of negative outcome in both diabetes management and surgical procedures in these patients. The reported role of AGEs prompted the development of pharmacological inhibitors of their effects, giving rise to a number of both preclinical and clinical studies. Clinical trials with anti-AGEs drugs have been gradually developed and this review aimed to summarize most relevant reports.

Evidence Acquisition: Evidence acquisition process was performed using PubMed and ClinicalTrials.gov with manually checked articles.

Results: Pharmacological approaches in humans include aminoguanidine, pyridoxamine, benfotiamine, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, statin, ALT-711 (alagebrium) and thiazolidinediones. The most recent promising anti-AGEs agents are statins, alagebrium and thiazolidinediones. The role of AGEs in disease and new compounds interfering with their effects are currently under investigation in preclinical settings and these newer anti-AGEs drugs would undergo clinical evaluation in the next years. Compounds with anti-AGEs activity but still not available for clinical scenarios are ALT-946, OPB-9195, tenilsetam, LR-90, TM2002, sRAGE and PEDF.

Conclusions: Despite most studies confirm the efficacy of these pharmacological approaches, other reports produced conflicting evidences; in almost any case, these drugs were well tolerated. At present, AGEs measurement has still not taken a precise role in clinical practice, but its relevance as a marker of disease has been widely shown; therefore, it is important for clinicians to understand the value of new cardiovascular risk factors. Findings from the current and future clinical trials may help in determining the role of AGEs and the benefits of anti-AGEs treatment in cardiovascular disease.

Keywords: Glycosylation End Products, Advanced; Diabetic Cardiomyopathies; Pimagedine; Pyridoxamine; Benphothiamine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Alagebrium; Thiazolidinediones

1. Context

Advanced Glycation End-Products (AGEs) are ubiquitous signaling proteins related to vascular and neurological complications of diabetes. They include various compounds formed by the Maillard reaction, which is a non-enzymatic glycation of free amino groups by sugars and aldehydes. AGE formation begins under hyperglycemic or oxidative stress conditions and is characterized by conversion of reversible Schiff-base adducts to covalently bound Amadori products, which undergo further rearrangements that terminate in the formation of irreversibly bound compounds known as AGEs (1). These reactions can be triggered by glucose-6-phosphate, glyceraldehydes-3-phosphate, glyoxal (GO), methylglyoxal (MGO) and 3-deoxyglucosone (3DG) (2). AGEs serum levels have been associated to several vascular and neurological complications, especially in the cardiovascular field and a flourishing production of literature is pointing at AGEs as a marker of negative outcome in both diabetes management and surgical procedures on these patients (3, 4). Detection and measurement techniques for AGEs have been gradually improved over the past 10 years starting from antibody and immune-based methods to the new readily available skin auto fluorescence techniques, which hold a promise for future bedside management of patients with diabetes (5). The reported role of AGEs in vascular complications of diabetes and cardiovascular...
lar disease also prompted the development of pharmacological inhibitors of their effects, giving rise to many experimental activities and a number of both preclinical and clinical studies. Although most studies confirm the usefulness of these pharmacological approaches, other reports produced contradictory findings. This review aimed to summarize most relevant issues in anti-AGE treatment, considering clinical experience in cardiovascular disease and discuss the potential benefits inhering their use in the clinical side.

1.1. AGES Pathophysiology and Mechanisms of Action

AGES damage cells and tissues through different mechanisms: intracellular glycation of proteins, which leads to impaired cell function; binding of circulating AGES to cellular receptors, with activation of signal transduction cascade and alteration of genes expression; accumulation of AGES in the extracellular matrix, which results in cross-linking and diminished vessels compliance.

1.1.1. Intracellular Glycation of Protein

Under high-glucose level conditions in endothelial cells, basic fibroblast growth factor (bFGF) undergoes increased glycation resulting in reduced mitogenic activity (6). Intracellular AGE formation reduces the expression of endothelial NO synthase (eNOS) and inactivates nitric oxide (NO); this explains the impaired vasodilatory response that occurs in diabetes (7). In diabetic rats, MGO-induced modifications of mitochondrial proteins were associated with increased superoxide formation in mitochondria (8). Furthermore, MGO modifies glutathione reductase and glutathione peroxidase, resulting in increased oxidative stress (9). MGO also impairs proteasome function (10) and alters overall cellular function (11).

1.1.2 Binding of Circulating AGES to Cellular Receptors

After diffusion from the cell, circulating AGES can bind to receptors on different cells, with activation of signaling pathways. Numerous AGE-binding proteins have been identified, such as macrophage scavenger receptors, AGE-R1, AGE-R2 and RAGE (12). The most studied receptor for AGES is RAGE, a member of the immunoglobulin superfamily expressed in most tissues (13). Apart from AGES, other ligands for RAGE include members of the St100/calgranulin family and high-mobility group box-1 (14). AGES binding to RAGE induces signaling pathways of mitogen-activated protein kinases (MAPK) (15), cdc42/rac and Jak/STAT (16), which modulate expression of genes for endothelin-1, vascular cell adhesion molecule 1 (VCAM-1), E-selectin, vascular endothelial growth factor (VEGF), inflammatory cytokines and others (17). RAGE expression is down regulated by peroxisome proliferator-activated receptor gamma (PPARγ) activation (18). Activation of AGE–RAGE axis increases self-expression of RAGE and NFkB-p65, which leads to a continuation and amplification of the signaling pathways and inflammation (19). Studies on diabetic mice confirmed the role of RAGE in the development of vascular alterations (20). The AGE–RAGE interaction determines a proliferation and activation of smooth muscle cell via angiotensin-2 pathway, with a possible explanation for accelerated atherosclerosis in diabetes (21).

1.1.3 Accumulation of AGES in the Extracellular Matrix

AGE-RAGE activation increases transforming growth factor beta-1 (TGF-β1) levels, with enhanced activity of matrix metalloproteinase 2 (MMP-2); on the other hand, RAGE signaling promotes MMP-9 activity. These factors determine alterations in collagen IV turnover (22). Extracellular matrix (ECM) is highly susceptible for glycation because of its slow turnover rate, and AGE accumulation is responsible for the formation of cross-links (23), with subsequent mechanical alterations (24) leading to decreased elasticity and increased stiffness of vessels (25) and myocardium (26), increased thickness, narrowing of the vessel lumen (27), development of glomerular sclerosis and atherosclerosis. AGE formation in ECM also interferes with matrix-cell interactions, with alterations in signaling and adhesion; these may be an important initial event in diabetic microangiopathy (28). AGE production induces apoptosis in macrophages followed by the osteogenic differentiation of aortic smooth muscle cells, resulting in atherosclerotic vascular calcifications (29).

1.2. AGES in Cardiovascular Disease

AGES have been shown to induce inflammation and intracellular Reactive Oxygen Species (ROS), which leads to the expression of many atherosclerosis-related genes, including VEGF (30). AGE increases the levels of Low-Density Lipoprotein (LDL) through a reduction in its plasma clearance, contributing to atherosclerosis (31). Elevated serum AGES were found in patients with coronary artery disease (32) and associated with aortic stiffness and correlated with disease severity (33). AGE deposits have been found in atherosclerotic plaques and within myocardium fibers (34, 35). Serum levels of AGES are associated with markers of left ventricular diastolic dysfunction (36). Furthermore, AGE levels are higher in case of peripheral artery disease in patients with diabetes (3). Receptors for AGES (RAGE) have been found to be overexpressed in carotid artery explants, as the vulnerable area of the plaque and have been related with inflammatory reactions (37). The soluble form of the extracellular domain of RAGE is known as sRAGE, which is able to prevent AGE-RAGE interaction, thus blocking the signal transduction pathway ultimately leading to cellular damage (38). AGES also provide prog-
nostic information about operative outcome and success rate of interventions in cardiovascular disease. In patients with diabetes undergoing percutaneous coronary intervention (PCI) with balloon angioplasty or bare-metal stent (BMS) implantation, elevated levels of serum AGEs were a risk factor for development of intra-stent restenosis (39). The prospective ARMYDA-AGES Study (40) showed that in patients with diabetes on optimized glycemic control who underwent PCI with drug-eluting stent (DES) implantation, high AGEs levels in plasma were an independent predictor of intra-stent restenosis and stent lumen loss at six months. Thus, AGE levels represent a valuable marker of adverse outcome after PCI (41). Plasmatic AGE levels can predict heart failure and new cardiac events (42, 43) and proved to be better than HbA1C measurements in predicting the progression of diabetic complication (44). In patients with diabetes, with HbA1C < 6.0% and without clinically relevant complications, serum levels of AGEs were higher in comparison to a control normoglycemic cohort with comparable HbA1C and determine a prothrombotic state, which might explain the increased rate of vein graft failure after surgical myocardial revascularization (45). In fact, AGEs activated RAGE expression, inhibited PPARγ expression, enhanced intracellular ROS formation and increased neutrophil-endothelial adhesion. AGE levels were proved to be associated with poor outcome and adverse events in patients after cardiac surgery; AGEs were also related with prolonged intubations and long hospitalization in Intensive Care Unit (46). Increased serum levels of AGEs, as well as skin tissue values (47), can predict total and cardiovascular mortality in patients with diabetes during a long term follow-up (4).

2. Evidence Acquisition

Evidence acquisition process was performed on PubMed (www.ncbi.nlm.nih.gov/pubmed) and ClinicalTrials.gov. Search terms included "AGEs, advanced glycation end products, cardiovascular disease, cardiac, diabetes, drugs", with manually checked articles.

3. Results

A number of drugs had been developed to interfere with the glycation pathway. Despite most of them are solely used in preclinical settings, some are approved for human treatment. Albeit a detailed discussion of the mechanism of actions and preclinical findings of these compounds exceeds the purpose of this review, a schematic description of each anti-AGEs compound is provided in Table 1. Results of human clinical trials with inherent each compound would be described in details below and are summarized in Table 2.

| Table 1. Anti-AGEs Compounds | 
|-----------------------------|
| **Drug** | **Mechanism of Anti-AGEs Activity** |
| Aminoguanidine | Post-Amadori inhibitor by trapping dicarbonyl intermediates, NOS inhibitor |
| Pyridoxamine | Prevents the transformation of protein-Amadori intermediates to protein-AGE products, post-Amadori inhibitor by trapping carbonyl intermediates |
| Benfotiamine | Post-Amadori inhibitor by trapping dicarbonyl intermediates |
| ACEIs | Pre-Amadori and post-Amadori inhibitor, transition metal ion chelator |
| ARBs | Agonist of PPARγ |
| Statins | Stimulate RAGE shedding |
| Alagebrium (ALT-711) | Breaks carbon-carbon bonds between carbonyls (*AGE-breaker*) |
| TZDs | Agonist of PPARγ, Reduces RAGE Expression |
| ALT-946 | Post-Amadori inhibitor by trapping dicarbonyl intermediates, NOS inhibitor |
| OPB-9195 | Post-Amadori inhibitor by trapping dicarbonyl intermediates, agonist of PPARγ |
| Tenilsetam | Post-Amadori inhibitor by trapping dicarbonyl intermediates, transition metal ion chelator |
| LR-90 | Post-Amadori inhibitor by trapping dicarbonyl intermediates, transition metal ion chelator |
| TM2002 | Transition metal ion chelator |
| sRAGE | Prevents AGE binding to RAGE |
| PEDF | Serine-protease inhibitor which reduces AGE-RAGE signal transduction, activation of PPARγ signal transduction |

**Abbreviations:** ACEIs: Angiotensin Converting Enzyme Inhibitors. ARBs: Angiotensin Receptor Blockers. NOS: Nitric Oxide Synthase. TZDs: Thiazolidinediones.

**b** No human data with this agent has been published.
### Table 2. Summary of Clinical Trials About Compounds Interfering With the Glycation Pathway

| Study                  | Type            | Drug            | Cohort   | Duration of Treatment | Effect of Anti-AGEs Drug                                                                 |
|------------------------|-----------------|-----------------|----------|-----------------------|-----------------------------------------------------------------------------------------|
| ACTION (2004) (48)     | R, DB, PC       | aminoguanidine  | 690 T1DM | 2-4 years             | No beneficial effects in progression of overt nephropathy. Modest attenuation of complications of diabetes mellitus |
| ACTION 2 (1999) (49)  | R, DB, PC, M    | aminoguanidine  | 599 T2DM | Not Available         | Unpublished data. Study discontinued due to lack of efficacy and safety concerns         |
| Williams et al. (2007) | R, DB, PC, M    | pyridoxamine    | 212 T1/2DM | 6 months             | Beneficial reduction from baseline in serum creatinine                                   |
| Stirban et al. (2006)  | O               | benfotiamine    | 33 T2DM  | 3 days                | Beneficial reduction in AGE levels and markers of oxidative stress                      |
| Rabbani et al. (2009) | R, PC           | thiamine        | 40 T2DM  | 3 months              | Beneficial reduction in urinary albumin excretion                                       |
| Fraser et al. (2012)  | R, DB, PC       | benfotiamine    | 67 T1DM  | 2 years               | No changes in peripheral nerve function or inflammatory markers                          |
| Alkhalaf et al. (2010) | R, DB, PC       | benfotiamine    | 82 T2DM  | 3 months              | No changes in 24 h urinary albumin excretion or injury molecules                        |
| Alkhalaf et al. (2012) | R, DB, PC       | benfotiamine    | 82 T2DM  | 3 months              | No changes in plasma or urinary AGES. No changes in plasma markers of endothelial dysfunction and inflammation. No clinical benefit |
| Sebekova et al. (2003) | PC              | ramipril        | 29 T2DM  | 2 months              | Reduced fluorescent AGES. Reduction in blood pressure and proteinuria. No changes in creatinine clearance |
| Komiya et al. (2008)  | O               | valsartan       | 15 T2DM  | 1 year                | Reduced AGES levels. No changes in oxidative markers. Decline in microalbumin levels in urine not statistically significant. No changes in carotid artery intima-media thickness |
| Ono et al. (2013) (60) | O               | candesartan     | 25T2DM   | 3 months              | Reduced urinary excretion of AGES and albumin                                          |
| Saha et al. (2010)    | PC              | candesartan     | 32 T2DM  | 3 months              | Reduction in CML. Slightly increase in creatinine clearance                             |
| Scharnagl et al. (2007) | R, DB, PC, M   | cerivastatin    | 69 IGT/DM | 3 months              | Beneficial reduction in AGE, cholesterol, apoB and LDL levels                          |
| Cuccurullo et al. (2006) | R, O           | simvastatin     | 70 T2DM  | 4 months              | Beneficial reduction in carotid plaque RAGE expression through diminished AGE generation. Might cause plaque stabilization by inhibiting PGE2-dependent MMP, responsible for plaque rupture |
| Nakamura et al. (2010) | O               | atorvastatin    | 30 CKD   | 1 year                | Reduction from baseline in proteinuria and AGES levels. No changes in glomerular filtration rate |
| Kass et al. (2001)    | R, DB, PC, M    | alagebrium      | 93 SH    | 2 months              | Beneficial increment in total arterial compliance, beneficial diminished arterial pulse pressure. No effects on systemic arterial resistance, cardiac output and heart rate |
| Little et al. (2005)  | O               | alagebrium      | 23 diastolic HF | 4 months         | Beneficial decrease in left ventricular mass. Beneficial increase in left ventricular diastolic filling and quality of life |
| Zieman et al. (2007)  | DB              | alagebrium      | 13 SH    | 2.5 months            | Beneficial increase in arterial endothelial function. Might reduce arterial stiffness and vascular remodeling |
| BENEFICIAL (2010) (67) | R, DB, PC       | alagebrium      | 102 systolic HF | 9 months       | No changes in exercise tolerance, diastolic and systolic function, AGE accumulation, NT-pro-BNP and NYHA functional class |
| Oudegeest-Sander et al. (2013) (69) | R, DB, PC       | alagebrium      | 48 sedentary life | 1 year         | No changes in vascular function. Lack in potentiating the effect of exercise training |
| Fujimoto et al. (2013) | R, DB, PC       | alagebrium      | 62 sedentary life | 1 year         | No changes in hemodynamic, left ventricular geometry, exercise capacity. Might have favorable effect in age-related left ventricular stiffening |
| Oz Gui et al. (2010)  | R, PC           | pioglitazone    | 62 T2DM  | 3 months              | Increase in sRAGE levels                                                                |
| Gada et al. (2013)    | R, PC           | rosiglitazone   | 111 T2DM | 6 months              | Increase in sRAGE levels. Reduction in other 3 protective markers indicating a negative effect |
| PioRAGE (2014) (38)   | R, PC           | pioglitazone    | 63 T2DM  | 6 months              | Reduced RAGE and increased sRAGE expression                                             |

Abbreviations: CKD: Chronic Kidney Disease. DB: Double Blinded. DM: Diabetes Mellitus. HF: Heart Failure. IGT: Impaired Glucose Tolerance. M: Multicentric. MMP: Matrix Metalloproteinase. O: Open. PC: Placebo-Controlled. R: Randomized. SH: Systolic Hypertension.
3.1. Aminoguanidine (Pimagedine)

ACTION trial evaluated the safety and efficacy of aminoguanidine regarding the rate of progression of diabetic nephropathy. Overall, 690 patients with type-1 diabetes with known diagnosis of nephropathy and retinopathy were enrolled. After 2-4 years, aminoguanidine therapy was successful in reducing 24-hour proteinuria and in preventing the decrease in glomerular filtration rate. On the other hand, the effect on serum creatinine levels was not significant. Moreover, a minority of patients treated with aminoguanidine, in comparison with controls, experienced a progression of retinopathy. Overall, this study demonstrated that inhibiting AGEs production can result in a clinically significant attenuation of diabetes complications (48). ACTION II compared aminoguanidine with placebo on the progression of renal disease in 599 patients with type-2 diabetes and nephropathy. Side effects in high dose arm of the study, such as flu-like symptoms, hepatic abnormalities, gastrointestinal disturbances and anemia, caused an early discontinuation of this study, which failed to prove a role for aminoguanidine (49).

3.2. Pyridoxamine

Pyridoxamine reduced change from baseline in serum creatinine and urinary TGFβ excretion after a 6-month treatment in 212 patients with diabetes and nephropathy (50). A study reported an accelerated decline in renal function in case of vitamin B6, B9 and B12 cotherapy (51), but vitamin B6 is unlikely to be the cause (52), and thus pyridoxamine treatment seems to be safe.

3.3. Benfotiamine

Benfotiamine, proved to prevent endothelial dysfunction and oxidative stress in patients with diabetes receiving a meal rich in AGEs (53). In 40 type-2 diabetic patients with microalbuminuria, thiamine administration for three months determined a regression in urinary albumin excretion (UAE) (54). Conversely, a study performed in 2010 on 82 patients with diabetes and advanced renal disease treated with benfotiamine or placebo for three months failed to reduce UAE (55). The same group in 2012 proved that in 82 patients with type-2 diabetes, benfotiamine treatment for three months did not reduce plasma or urinary AGEs, markers of endothelial dysfunction and inflammation; hyperglycemia-induced vascular complications were not clinically improved (56). In 67 patients with diabetes and neuropathy, benfotiamine administration for two years did not significantly improve peripheral nerve function or reduced markers of inflammation (57).

3.4. Angiotensin Converting Enzyme Inhibitors

In 2003, a study enrolled 29 patients, 12 of which had diabetes and treated with ramipril, to evaluate its effect on AGEs formation and oxidative stress. After two months, ramipril reduced blood pressure, proteinuria and fluorescent AGEs, despite unchanged creatinine clearance and N (ε)-carboxy-methyl-lysine (CML) concentration (58).

3.5. Angiotensin Receptor Blockers

In 2008, 15 patients with diabetes and hypertension were treated with valsartan to study its effect on AGEs. At one year follow-up, a significant decrease in AGEs levels was demonstrated. However, there were no changes in oxidative markers and in carotid artery intima-media thickness, and the decline in urine albumin levels was not statistically significant (59). Another study demonstrated that in 25 patients with diabetes and hypertension treated with candesartan for three months, urinary excretion of AGEs and albumin were reduced compared to baseline (60). In 2010, 32 patients, 11 of which diabetics with significant proteinuria, were treated with candesartan for three months, observing a reduction in CML and a slightly increase in creatinine clearance (61).

3.6. Statin

A study examined the effect of cerivastatin on serum concentration of AGEs in 69 patients with diabetes or pre-diabetes (62). After a 3-month treatment, cerivastatin improved lipids profile and decreased CML levels. Another study considered atherosclerotic plaques and the effect of statin treatment on their expression of RAGE and destabilizing genes; simvastatin was administered in 70 patients for four months before carotid endarterectomy and intraoperative samples examination concluded that simvastatin inhibits RAGE expression through a decrease in myeloperoxidase-dependent AGE production. In addition, an inhibition of matrix metalloproteases was reported, thus contributing to plaque stabilization through reduced inflammation (63). In another study on 10 patients with dyslipidemia and chronic kidney disease without diabetes treated with atorvastatin, atorvastatin treatment for one year determined a reduction in proteinuria and AGEs levels, though not affecting glomerular filtration rate (64).

3.7. ALT-711 (Alagebrium)

Alagebrium has been extensively investigated in a number of clinical trials, sponsored by Synvista Therapeutics from 2002 to 2010 (DIAMOND (NCT00043836), SAPPHIRE (NCT00045981), SILVER (NCT00045994), SPECTRA (NCT00089713), BREAK-DHF-I (NCT00662116) and BENEFICIAL (NCT00516646). However, few data had been officially published, and some of these studies had been terminated early due to financial constraints. In 2001, a pilot study enrolled 93 patients with hypertension randomized to placebo or alagebrium. After two months, patients in the treatment arm experienced a decrease in arterial pulse pressure with a concomitant increase in arterial pulse pressure with a concomitant increase in arterial pulse pressure with a concomitant increase in arterial pulse pressure with a concomitant increase in arterial pulse pressure with a concomitant increase in
vessel compliance (26). In 23 patients with diastolic heart failure, alagebrium administration for four months determined a decrease in left ventricular mass and improvements in diastolic filling (65). Another small study considered 13 patients with hypertension, treated for 10 weeks and concluded that alagebrium enhanced endothelial function and might play a role in reducing arterial remodeling (66). However, the BENEFICIAL trial (67) enrolling 102 patients with systolic heart failure, showed that alagebrium, despite being well tolerated, did not improve exercise tolerance, diastolic or systolic function, AGE accumulation, N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) level or New York Heart Association (NYHA) class after 9-month treatment (68).

A recent study (69) enrolled 48 healthy individuals with sedentary life, who were randomized into four groups; training + alagebrium, training + placebo, no training + alagebrium and no training + placebo. After one year of treatment, endothelial function and arterial stiffness did not change and alagebrium treatment had no independent or synergic effect on vascular function. Another study (70) randomized 62 healthy individuals into four groups in a similar way and subjects underwent heart catheterization to define hemodynamics. After one year of treatment, alagebrium had no effect on hemodynamics, left ventricular shape or exercise capacity, but improved left ventricular stiffness.

3.8. Thiazolidinediones

Thiazolidinediones, known as oral and well-tolerated drugs for diabetes, proved to have a role in anti-AGE treatment because of their PPARY-agonist activity, which determines an increase in sRAGE expression, which is inversely associated with atherosclerosis. A study conducted in 2010 (71) on 62 patients with diabetes who received pioglitazone, rosiglitazone or placebo showed that pioglitazone but not rosiglitazone was able to significantly raise sRAGE at 12 weeks follow-up. However, another randomized placebo-controlled study conducted in 2013 (72) enrolling 111 patients with type-2 diabetes and at high risk of coronary heart disease, tested the effects of rosiglitazone after six months of treatment. Level of sRAGE were augmented, together with high-sensitivity C-reactive protein (hsCRP) indicating a protective effect on inflammatory process. Pioglitazone trial (38) involved 63 patients with type-2 diabetes, randomly assigned to pioglitazone or placebo showed that pioglitazone but not rosiglitazone was able to significantly suppress RAGE expression and increase plasma levels of sRAGE, independently on glycaemia effect or insulin resistance index.

4. Conclusions

Considering the overall results of these studies, anti-AGEs drugs would be an attractive clinical option in the near future. The apparent lack of benefits in some trials might be related to the small sample size or the short follow-up period. In addition, there is no general agreement or evidences about the dose for each drug, which differs among various studies; this mined the possibility to perform a reliable comparison. We reliably speculate that some discordant results might have conspired against widespread use of these agents. However, considering many preclinical studies on the role of AGEs as both a marker and a cause of disease and on new compounds interfering with their effects, we might expect a forthcoming production of clinical evaluation of new anti-AGEs drugs. The most recent promising anti-AGEs agents are statins, alagebrium and thiazolidinediones even if remains unclear which patients would benefit more. Another point emerging is that AGEs measurement has still not taken a pivotal and widespread role in clinical practice. It is important for clinicians to critically appraise the value of new cardiovascular risk factors. Diabetes mellitus remains a major determinant for prognosis, but using exclusively glycaemia and glycated hemoglobin to assess the state, prognosis or outcome of patients with diabetes is not appropriate anymore. AGE levels add new information for the development and progression of cardiovascular disease in both diabetic and non-diabetic patients, because AGE accumulation occurs before than glycated hemoglobin and more closely correlates with the severity of the disease, predicting the development of cardiovascular complications. A variety of interventions against AGE accumulation, predominantly tested in preclinical contexts, appear to show beneficial effects on the development of diabetic complications and cardiovascular diseases. Findings from the current and future clinical trials may help in determining optimal therapeutic target of AGEs in cardiovascular disease.

Authors’ Contributions

1- Study concept and design: Cristiano Spadaccio. 2- Acquisition of data: Antonio Nenna, Sanjeet Singh Avtaar Singh. 3- Analysis and interpretation of data: Antonio Nenna, Francesco Nappi. 4- Drafting of the manuscript: Antonio Nenna, Sanjeet Singh Avtaar Singh, Cristiano Spadaccio. 5- Critical revision of the manuscript for important intellectual content: Francesco Nappi, Fabio Di Domenico, Fraser W Sutherland. 6- Statistical analysis: Antonio Nenna. 7- Administrative, technical and material supports: Massimo Chello, Fraser W Sutherland. 8- Study supervision: Cristiano Spadaccio, Massimo Chello.

References

1. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res. 2005;56:1-21.
2. Thornalley PJ. Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci. 2005;1043:331-7.
3. Lapolla A, Parulli F, Sartore G, Cesiello A, Ragazzi E, Reitano R, et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care. 2007;30(3):570-6.
4. Bihovh BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, et al. Increased serum levels of advanced glycation

Nenna A et al.
Res Cardiovasc Med. 2015;4(2):e26949
end products predict total, cardiovascular and_coronal mortality
in women with type 2 diabetes: a population-based 18 year
follow-up study. Diabetologia. 2007;50(7):1409-17.

5. Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, et al. Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study. PLoS One 2013;8(2):e5799.

6. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosyla-
tion in vitro and in bovine endothelial cells alters basic fibro- 
blast growth factor activity. A model for intracellular glycosyla-
tion in diabetes. J Clin Invest. 1994;94(1):310-7.

7. Soro-Paavonen A, Zhang WZ, Venkata K, Coughlan MT, Harris E, Tong DC, et al. Advanced glycation end-products induce vasu-
lar dysfunction via resistance to nitric oxide and suppression of 
endothelial nitric oxide synthase. Hypertens. 2002;28(4):780-8.

8. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, S weda LJ, et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol. 2005;289(3):F420-30.

9. Wu L, Juru-link BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension. 2002;39(3):309-14.

10. Queisser MA, Yao D, Geisler S, Hammes HP, Lochnit G, Schleicher ED, et al. Hyperglycemia impairs prostate function by methyl-
glyoxal. Diabetes. 2003;52(9):2670-8.

11. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, et al. High glucose increases angiotensin-2 transcription in microvascular endothelial cells by methylglyoxal modifi-
cation of mSin3A. J Biol Chem. 2007;282(4):31038-45.

12. Vlassara H, Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end-prod-
uct receptors. Diabetes. 1996;45 Suppl 3:S65-6.

13. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010;106(5):842-53.

14. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflam-
mation, immune responses and diabetes mellitus and its com-
plications. Diabetologia. 2009;52(1):225-31.

15. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atheroscle-
sis. Circ Res. 1999;84(3):589-97.

16. Bierhaus A, Humphert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glyca-
ation end products. J Mol Med (Berl). 2005;83(11):1076-86.

17. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glyca-
tion end products: sparking the development of diabetic vascular 
injury. Circulation. 2006;114(9):1159-65.

18. Liang Y, Chen S-A, Jia H. Peroxisome proliferator-activated receptor δ downregulates the expression of the receptor for ad-
vanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice. Europ J Pharmacol Sci. 2011;4(3):165-70.

19. Bierhaus A, Schiekofer S, Schwanger M, Andressy M, Hump-
ert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes. 2005;54(12):2792-808.

20. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, et al. RAGE-induced cytosolic ROS promote mito-
ochondrial superoxide generation in diabetes. J Am Soc Nephrol. 2009;20(4):742-52.

21. Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB. STZ-induced augmentation of angiotensin II-induced activation of Jak2 in vascular smooth muscle cells is dependent on PLD2. Diabetes. 2003;52(9):2381-8.

22. Serban AI, Stanca I, Geoiu OI, Munteanu MC, Costache M, Dinis-
chiotu A. Extracellular matrix is modulated in advanced gly-
cation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-beta RAGE. J Diabetes. 2015;7(1):34-24.

23. Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation - a mini-review. Gerontology. 2012;58(3):227-37.

24. Greenland SE. Ageing of the conduit arteries. J Pathol. 2007;211(2):157-72.

25. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glyca-
tion cross-links in diabetic vascular stiffening. Diabetologia. 1996;39(6):946-51.

26. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, de-
Groof RC, et al. Improved arterial compliance by a novel ad-
vanced glycation end-product crosslink breaker. Circulation. 2001;104(1):1644-70.

27. McNulty M, Mahmud A, Feely J. Advanced glycation end-pro-
ducts and arterial stiffness in hypertension. Am J Hypertens. 2007;20(2):244-7.

28. Schalkwijk CG, Miya A, Early- and advanced non-enzymatic gly-
cation in diabetic vascular complications: the search for thera-
picines. Amino Acids. 2012;42(4):1993-204.

29. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, et al. Advanced glyca-
tion end-product N epsilon-carboxymethyllysine accelerates progression of atherosclerotic calcification in diabetes. Athero-
sclerosis. 2012;222(2):387-96.

30. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 2010;45(4):267-274.

31. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem. 1995;270(59):30828-32.

32. Kanazaki M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care. 2010;34(5):2620-10.

33. Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic pa-
patients. Heart. 2005;91(1):89-91.

34. Schalkwijk CG, Badoshvili A, Stenhoffer CD, van Hinsbergh VW, Niessen HW. Increased accumulation of the glycoxidation product N epsilon-carboxymethyllysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-
CMII antibody. Biochim Biophys Acta. 2004;1636(2-3):52-9.

35. Sakata N, Meng J, Jims L, Takebayashi S. Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Atherosclerosis. 1995;116(1):63-75.

36. Berg T, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Melsen J, et al. Serum levels of advanced glycation end products are associ-
ated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. 1999;22(7):1166-90.

37. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, et al. The receptor RAGE as a progression factor amplifying arachi-
donate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glyceric control. Circu-
lation. 2013;128(9):1070-7.

38. Koyama H, Tanaka S, Monden M, Shoji T, Morita I, Fukumoto S, et al. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mono-
nuclear cells in type 2 diabetes: randomized controlled trial (Pi-
RAGE). Atherosclerosis. 2004;184(2-3):329-34.

39. Choi EY, Kwon HM, Ahn CW, Lee GT, Joung B, Hong BK, et al. Serum levels of advanced glycation end products are associ-
ated with in-stent restenosis in diabetic patients. Yonsei Med J. 2005;46(1):78-85.

40. Spadaccio C, Patti G, De Marco F, Coccia R, Di Domenico P, Pollari F, et al. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMDA-AGES Study). Am J Cardiol. 2011;108(1):21-6.

41. Fukushima Y, Daida H, Morimoto T, Kasi T, Miyashiki K, Yamagi-
shi S, et al. Relationship between advanced glycation end prod-
ucts and plaque progression in patients with acute coronary syn-
donome: the JAPAN-ACS sub-study. Cardiovasc Diabetol. 2011;10:5.

42. Koyama T, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail. 2007;13(3):399-206.
43. Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smidé TD, Damman K, et al. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. *Europ Heart J*. 2007;28(23):2879-85.

44. Wolfenbuttel BH, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. *Lancet*. 1996;347(9000):333-7.

45. Chello M, Spadaccio C, Lusini M, Covino E, Blazarino C, De Marco F, et al. Advanced glycation end products in diabetic patients with optimized glycemic control and their effects on endothelial reactivity: possible implications in venous graft failure. *Diabetes Metab Res Rev*. 2009;25(5):420-6.

46. Simm A, Wagner J, Gursinsky T, Nass N, Friedich I, Schinzel R, et al. Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery? *Exp Gerontol*. 2007;42(7):668-75.

47. Meerwaldt R, Lutgers HI, Links TP, Graaff R, Baynes JW, Gans RO, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. *Diabetes Care*. 2007;30(1):97-12.

48. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *Am J Nephrol*. 2004;24(1):32-40.

49. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, et al. Design and baseline characteristics for the aminoguanidine-dine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). *Control Clin Trials*. 1999;20(5):491-510.

50. Williams ME, Bolton WK, Khalifa RG, Deegenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. *Am J Nephrol*. 2007;27(6):609-14.

51. House AA, Ellassiw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. *JAMA*. 2010;303(16):1603-9.

52. Thormaely P, Rabbani N, Therapy; Vitamin B6, B9 and B12 in diabetic nephropathy-beware. *Nat Rev Endocrinol*. 2010;6(9):477-8.

53. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. *Diabetes Care*. 2006;29(9):2064-71.

54. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. *Diabetologia*. 2009;52(2):208-12.

55. Alkhalf A, Klooster A, van Oeveren W, Achenbach U, Kleezstra F, Slingerland RJ, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. *Diabetes Care*. 2010;33(7):1358-61.

56. Alkhalf A, Kleezstra F, Groenier KH, Bilo HJ, Gans RO, Heeringa P, et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. *PLoS One*. 2012;7(7):e40427.

57. Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljelid I, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. *Diabetes Care*. 2012;35(5):1095-7.

58. Sebekova K, Gazidkova K, Syrova D, Blazieck P, Schinzel R, Heidland A, et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidative stress and potential modulation of advanced glycation end products. *J Hum Hypertens*. 2003;17(4):265-70.

59. Komiya N, Hirose H, Saisho Y, Saito I, Itoh H. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. *Int Heart J*. 2008;49(5):681-9.

60. Ono Y, Mizuno K, Takahashi M, Miura Y, Watanabe T. Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. *Fukushima J Med Sci*. 2013;59(2):69-75.

61. Saha SA, Lalshale BR, Clifton GD, Short RA, Tuttle KR. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study. *Am J Ther*. 2010;17(6):553-8.

62. Scharnagl H, Stojakovic T, Winkler K, Rosinger S, Marz W, Boehm BO. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. *Exp Clin Endocrinol Diabetes*. 2007;115(6):372-5.

63. Cuccurullo C, Jezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, et al. Suppression of RAGE as a basis of sinnvastatin-dependent plaque stabilization in type 2 diabetes. *Atherosclerosis Thromb Vasc Biol*. 2006;26(2):2716-23.

64. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Takeuchi M, Maeda S, et al. Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). *Oxid Med Cell Longev*. 2010;3(5):304-7.

65. Little WC, Zile MR, Kitzman DW, Hundley WG, O’Brien TE, DeGroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. *J Card Fail*. 2005;11(3):299-305.

66. Ziemann SJ, Melenovsky V, Clattenburg I, Corretti MC, Capriotti A, Gerstenblith G, et al. Advanced glycation end product crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. *J Hypertens*. 2007;25(3):577-83.

67. Willemsen S, Hartog JW, Hummel TM, Posma JL, van Wijk LM, van Veldhuisen DJ, et al. Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. *Eur J Heart Fail*. 2010;12(3):294-300.

68. Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, et al. Effects of alagebrium, an advanced glycation end product breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. *Eur J Heart Fail*. 2013;15(8):909-908.

69. Oudegeest-Sander MH, Olde Rikkert MG, Smits P, Thijssen DH, van Dijk AP, Levine BD, et al. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial. *Exp Gerontol*. 2013;48(12):2509-17.

70. Fujimoto N, Hastings JL, Carrick-Ranson G, Shafer KM, Shibata S, Hella P, et al. Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals. *Circ Heart Fail*. 2013;6(6):1355-64.

71. Oz Gul O, Tuncel E, Yilmaz Y, Ulukaya E, Gul CB, Kiyici S, et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. *Metabolism*. 2010;59(1):64-9.

72. Gada E, Owens AW, Gore MO, See R, Abdullah SM, Ayers CR, et al. Discordant effects of rosiglitazone on novel inflammatory biomarkers. *Am Heart J*. 2013;165(4):609-14.